Navigation Links
Niusule Biotech Corp. to Commence Trading on the OTC Bulletin Board Under the Symbol 'NIUS'
Date:12/30/2008

CARSON CITY, Nev., Dec. 30 /PRNewswire-FirstCall/ -- Niusule Biotech Corp., a Nevada corporation formed on April 8, 2008, announced today that its shares of common stock will begin trading on the OTC Bulletin Board under the symbol "NIUS" on December 30th, 2008.

For a NIUS quote, visit: http://finance.yahoo.com/q?s=NIUS.OB

"Our main business will be operated in China through our subsidiary Zhejiang Baitai Bioengineering Corp by manufacturing and selling biopharmaceutical and health food," said Qinghua Hu, Chairman of Niusule Biotech Corp. "We believe our public listing is a signal of Niusule Biotech Corp.'s maturity as a company. I would like to thank Niusule Biotech Corp.'s partners, employees and shareholders for their respective roles in contributing to our success."

In a meeting with employees, directors, and shareholders, Hu discussed Niusule Biotech Corp. goals and priorities as a publicly traded entity including:

    -- Build long-term value for shareholders by implementing our business
       plan;
    -- Seek cooperation and alliance with US companies manufacturing health
       food products for either distribution or production rights in China;
       and
    -- Commitment to being a leading player in China's health food industry
       and bioengineering industry.

"As we are in our initial stages of growth, we provide both small and institutional investors opportunities to invest in China's health food industry," said Hu. "The move to the OTC Bulletin Board positions the company to benefit from greater visibility and liquidity."

About Niusule Biotech Corp.

Founded in 2008, Niusule Biotech Corp.'s main business will be operated in China through our subsidiary Zhejiang Baitai Bioengineering Corp. Niusule Biotech Corp. is trying to build a bridge between the USA and China in the health food industry and bioengineering industry by accessing the talent pools in both countries and by applying the mature technologies and high quality standards of the USA to its business model in China.

For more information about Niusule Biotech Corp., visit http://www.niusule.com.

This news release contains forward-looking statements. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks described in the company's filings with the SEC.


'/>"/>
SOURCE Niusule Biotech Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bolder BioTechnology Receives $1.9 Million NIH Grant to Continue Development of Long-Acting Growth Hormone Product
2. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
3. Ganeden Biotech Receives Frost & Sullivan Probiotics Product Innovation Award
4. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
5. Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc.
6. Axial Biotech Launches Genetic Test for Adolescent Idiopathic Scoliosis (AIS)
7. Investor Group Reconfigures Proposed Slate of Replacement Directors for Trinity Biotech
8. The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health
9. Ernst & Young Benchmarks Danish Biotech Pipeline Third in Europe
10. Micromet Added to NASDAQ Biotechnology Index
11. Biotech Endorsement Insurance Discount Expanded to Nebraska, Kansas Growers Planting Corn with HERCULEX XTRA Traits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... will be hosting a Webinar titled, “Pathology is going digital. Is your lab ... digital pathology adoption best practices and how Proscia improves lab economics and realizes ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... compared the implantation and pregnancy rates in frozen and fresh in vitro ... of progesterone and maternal age to IVF success. , After comparing the results ...
(Date:10/10/2017)... DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... as part of its corporate rebranding initiative announced today. The bold new look ... its reach, as the company moves into a significant growth period. , It will ...
Breaking Biology Technology:
(Date:8/23/2017)... , Aug. 23, 2017  The general public,s help is being ... microbiome—the bacteria that live in and on the human body –and are ... The Microbiome ... the human microbiome, starting with the gut. The project's goal is to ... Photo credit: IBM ...
(Date:6/14/2017)... , June 15, 2017  IBM (NYSE: IBM ) ... international tech event dedicated to developing collaboration between startups and ... on June 15-17. During the event, nine startups will showcase ... value in various industries. France ... the international market, with a 30 percent increase in the ...
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
Breaking Biology News(10 mins):